Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (6150)	1/23/1999 7:29:00 PM
From: VLAD	Read Replies (1) \| Respond to of 7041

I believe that last Friday's announcement by Merck that it would not progress into phase III clinical trials on MK-869, their anti-depression drug that many hoped may be a multibillion dollar producer, is a good example of a respectable no hype company acknowledging that when a drug shows little success above placebo there is no reason to pursue further developments. IMO, had ZONA not pursued Vasomax even knowing that it has little effectiveness above placebo, it would mean the demise of the company. At this point in time Zonagen is Vasomax. Without all the dreams hopes and promises linked to Vasomax, Zonagen has no future. The Vasomax dream is still alive and well. Once the dream turns into reality I hope those who have there money parked in Zonagen will have the good sense to get out and park their money on a much less questionable product.